Skip to main content

Table 3 General study characteristics of the models evaluating routine HZ vaccination

From: Systematic review of models assessing the economic value of routine varicella and herpes zoster vaccination in high-income countries

Study Country Model type Time horizon Type of economic evaluation Perspective Discount rate (costs/health effects) Costing year and currency Funding source
Annemans et al. [65] Belgium Static Lifetime CEA; CUA Health care payer (with and without co-payments); societal 3 %/1.5 % 2007 EUR Industry
Bilcke et al. [38] Belgium Static Lifetime CEA; CUA Health care payer 3 %/1.5 % 2009a EUR Independent
Bilcke et al. [30] Belgium Dynamicb Various CEA; CUA Health care payer 3 %/1.5 % 2011a EUR Independent
Bresse et al. [66] France Static Lifetime CEA; CUA Health care payer (with and without co-payments) 4 %/4 %c 2010 EUR Industry
Brisson et al. [67] Canada Static Lifetime CUA Health care payer 5 %/5 % 2005 CAD Industry
de Boer et al. [40] Netherlands Static Up to 41 years CUA Health care payer; societal 4 %/1.5 % 2010 EUR Independent
Edmunds et al. [68] England and Wales Static Lifetime CEA; CUA Health care payer 3 %/3 % 1998 GBP Independent
Hornberger et al. [28] USA Static 30 years CUA Societal 3 %/3 % 2006 USD Independent
Moore et al. [69] UK Static Lifetime CEA; CUA Health care payer; societal 3.5 %/3.5 % 2006 GBP Industry
Najafzadeh et al. [26] Canada Static Lifetime CUA Health care payer 5 %/5 % 2008 CAD Independent
Pellissier et al. [70] USA Static Lifetime CUA Health care payer; societal 3 %/3 % 2006 USD Industry
Rothberg et al. [42] USA Static Not specified CUA Societal 3 %/3 % 2005 USD Independent
Szucs et al. [71] Switzerland Static Lifetime CEA; CUA Health care payer; societal 3.5 %/1.5 % 2010a CHF Industry
Ultsch et al. [39] Germany Static Lifetime CEA; CUA Health care payer; societal 3 %/3 % 2010 EUR Independent
van Hoek et al. [72] England and Wales Static Lifetime CUA Health care payer 3.5 %/3.5 % 2006 GBP Independent
van Hoek et al. [33] UK Dynamicb Infinite CUA Health care payer 3.5 %/3.5 % 2007 GBP Independent
van Lier et al. [41] Netherlands Static Not specified CUA Health care payer; societal 4 %/1.5 % 2008 EUR Independent
  1. CEA cost-effectiveness analysis; CUA cost-utility analysis
  2. aPersonal communication with the author or assumption
  3. bCombined evaluation of varicella and HZ vaccination
  4. cDiscount rate for costs and health effects was reduced to 2 % after 30 years
Back to article page

BMC Public Health

ISSN: 1471-2458

Contact us